![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novonesis AS | TG:NZM2 | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.60 | 1.05% | 57.50 | 57.16 | 57.50 | 57.50 | 56.60 | 56.84 | 983 | 16:20:10 |
6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation
As Novozymes just closed the combination with Chr. Hansen on January 29, and the annual report now is expected to be released on February 8, this announcement only contains unaudited numbers. Full audited financial statements as well as non-financial numbers will be released with the annual report on February 8. This result update allows us to provide selected numbers for Novozymes standalone as early as possible.
Ester Baiget, President & CEO: “I am very pleased with our performance in 2023 - a year characterized by changing market demand and inventory adjustments in certain industries. The strength of Novozymes’ diversified portfolio and end-market exposure enables us to capture growth opportunities as they arise, providing a solid overall performance. We delivered organic sales growth of 5% for the year with solid earnings and cash flows. We closed the combination with Chr. Hansen on January 29. Our new company, Novonesis, is better equipped to enable customers further address the ever-increasing needs for healthier lives and a healthier planet supported by our broad portfolio of innovative, value added biosolutions. Thank you to all stakeholders for supporting us in making Novonesis become a reality”.
Sales performance (unaudited)
Financial performance (unaudited)
Outlook 2023 | 12M 2023 | 12M 2022 | Q4 2023 | Q4 2022 | ||
Sales growth, organic | % | 4-6 | 5 | 9 | 6 | 11 |
EBIT margin, b.s.i.* | % | 25-26 | 25.4 | 26.4 | 25.1 | 23.4 |
ROIC incl. goodwill, b.s.i.* | % | 16-17 | 16.5 | 17.9 |
*Special items include costs related to the combination with Chr. Hansen
Other key events and information
Selected key data (unaudited)
12M 2023 | 12M 2022 | Q4 2023 | Q4 2022 | ||
Sales performance, organic | % | 5 | 9 | 6 | 11 |
Household Care | % | 5 | 1 | 10 | 4 |
Food, Beverages & Human Health | % | (2) | 10 | (4) | 16 |
Bioenergy | % | 23 | 25 | 20 | 22 |
Grain & Tech Processing | % | (6) | 10 | 2 | 5 |
Agriculture, Animal Health & Nutrition | % | 3 | 8 | (7) | 11 |
Sales | DKKm | 17,899 | 17,553 | 4,603 | 4,529 |
Sales performance, DKK | % | 2 | 17 | 2 | 18 |
Gross margin | % | 54.3 | 54.6 | 54.0 | 53.5 |
EBITDA | DKKm | 5,365 | 6,046 | 1,320 | 1,392 |
EBIT | DKKm | 3,976 | 4,561 | 955 | 1,022 |
EBIT margin | % | 22.2 | 26.0 | 20.7 | 22.6 |
EBIT before special items* | DKKm | 4,552 | 4,629 | 1,157 | 1,059 |
EBIT margin before special items* | % | 25.4 | 26.4 | 25.1 | 23.4 |
Net profit | DKKm | 3,039 | 3,686 | 695 | 877 |
Net investments excl. acquisitions | DKKm | 2,052 | 2,862 | 603 | 898 |
Free cash flow before acquisitions | DKKm | 2,100 | 1,144 | 519 | (314) |
NIBD/EBITDA | x | 1.2 | 1.0 | ||
ROIC, incl. goodwill | % | 14.4 | 17.6 | ||
ROIC, incl. goodwill, before special items* | % | 16.5 | 17.9 | ||
Special items* | DKKm | (576) | (68) | (202) | (37) |
EPS | 10.92 | 13.29 | 2.52 | 3.19 | |
EPS (diluted) | 10.88 | 13.19 | 2.51 | 3.18 | |
Avg. USD/DKK | 689 | 708 | 694 | 730 | |
*Special items include costs related to the combination with Chr. Hansen
Contact information | ||
Investor Relations | ||
Tobias Bjorklund | +45 3077 8682 | tobb@novozymes.com |
Anders Enevoldsen | +45 5350 1453 | adev@novozymes.com |
Media Relations | ||
Lina Danstrup | +45 3077 0552 | lind@novozymes.com |
Attachment
1 Year Novonesis AS Chart |
1 Month Novonesis AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions